The role of Pyruvate Kinase M2 in Chronic myelogenous Leukemia progression
碩士 === 國立陽明大學 === 醫學生物技術暨檢驗學系 === 104 === Chronic myelogenous leukemia (CML) is a type of cancer that begins in certain bone marrow blood-forming cells. It is a form of leukemia characterized by the increased and unregulated growth of predominantly myeloid cells in the bone marrow and the accumulati...
Main Authors: | Yi Chung, 鍾怡 |
---|---|
Other Authors: | Muh-Hwa Yang |
Format: | Others |
Language: | en_US |
Published: |
2016
|
Online Access: | http://ndltd.ncl.edu.tw/handle/52516784838481385354 |
Similar Items
-
The role of Lyn kinase in the development of imatinib resistance in chronic myelogenous leukemia
by: Camillo Porta, et al.
Published: (2011-12-01) -
Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy
by: Zhenshu Xu, et al.
Published: (2009-03-01) -
Chronic myelogenous leukemia in Libya
by: Itrat Mehdi, et al.
Published: (2012-07-01) -
Chronic myelogenous leukemia on target
by: Veronika Némethová, et al.
Published: (2018-07-01) -
Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?
by: Giovanni Martinelli, et al.
Published: (2009-02-01)